Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Syndax Pharmaceuticals (SNDX) Stock Price & Analysis

1,061 Followers

SNDX Stock Chart & Stats

$9.45-$0.09(-0.94%)
At close: 4:00 PM EST
$10$15$20Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$9.11 - $9.85
52-Week Range
$9.11 - $25.59
Previous Close
$9.54
Volume
N/A
Average Volume (3M)
3.51M
Market Cap
$858.87M
Enterprise Value
$1.85B
Total Cash (Recent Filing)
$427.10M
Total Debt (Recent Filing)
$589.41M
Price to Earnings (P/E)
―
Beta
1.20
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
-0.53
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Commercial Growth And Market Leadership

Revuforj is showing sustained commercial adoption, with strong year-over-year growth, broad account penetration, and leadership in its menin-inhibitor class. This scale can reinforce prescribing momentum, support durable revenue expansion, and provide a foundation for future indications.

Growing Collaboration Contribution

Niktimvo provides an increasingly meaningful recurring contribution alongside Revuforj, while improving margin economics strengthen the quality of revenue. Continued penetration in chronic GVHD could support cash generation and reduce reliance on a single commercial product.

Funded Commercial And Pipeline Execution

The reported cash position supports continued investment in commercial expansion, front-line trials, and earlier pipeline assets over the next several quarters. Funding visibility gives management flexibility to pursue multiple catalysts without immediately curtailing development priorities.

Bears Say

Deep Ongoing Unprofitability

Syndax remains materially unprofitable despite revenue growth and high gross margin. Persistent operating losses limit internally generated capital, make the path to sustainable earnings dependent on further scale, and could constrain investment flexibility if commercialization takes longer.

Cash Burn And Financing Pressure

Large recurring cash outflows mean the company is not yet self-funding its operations and development programs. Even with improvement from earlier periods, continued burn can consume liquidity over time and increase the importance of revenue growth, cost control, or additional financing.

Elevated Leverage And Negative Equity

Higher debt combined with negative equity signals a weakened capital base and reduced financial flexibility. This structure can increase pressure on future cash flows, limit capacity to absorb setbacks, and make funding commercial or pipeline expansion more challenging.

Syndax Pharmaceuticals News

SNDX FAQ

What was Syndax Pharmaceuticals’s price range in the past 12 months?
Syndax Pharmaceuticals lowest stock price was $9.11 and its highest was $25.59 in the past 12 months.
What is Syndax Pharmaceuticals’s market cap?
Syndax Pharmaceuticals’s market cap is $858.87M.
When is Syndax Pharmaceuticals’s upcoming earnings report date?
Syndax Pharmaceuticals’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 108 days.
How were Syndax Pharmaceuticals’s earnings last quarter?
Syndax Pharmaceuticals released its earnings results on Nov 02, 2026. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.504 by -$0.046.
Is Syndax Pharmaceuticals overvalued?
According to Wall Street analysts Syndax Pharmaceuticals’s price is currently Undervalued.
Does Syndax Pharmaceuticals pay dividends?
Syndax Pharmaceuticals does not currently pay dividends.
What is Syndax Pharmaceuticals’s EPS estimate?
Syndax Pharmaceuticals’s EPS estimate is -0.53.
How many shares outstanding does Syndax Pharmaceuticals have?
Syndax Pharmaceuticals has 90,028,260 shares outstanding.
What happened to Syndax Pharmaceuticals’s price movement after its last earnings report?
Syndax Pharmaceuticals reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.504. Following the earnings report the stock price went up 9.084%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals?
Hedge funds hold Syndax Pharmaceuticals shares: the largest hedge-fund position in Syndax Pharmaceuticals is 71,886,740 shares, and hedge funds increased their holdings by 859.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology